RxDoctor Payments Data

David Bohle, MD

Cardiovascular Disease · Elkin, NCNPI 1710966718

Payments from drug & device makers

$18,410in general payments, 2019–2025

Across 75 payments — averaging $245.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • Boehringer Ingelheim$6K
  • Lilly USA, LLC$4K
  • Amgen$256
  • Novartis$229
  • Johnson & Johnson$204
  • plus $290 from 5 others

What the payments were for

  • Consulting fees$9005%
  • Speaking & faculty fees$15,15082%
  • Travel & lodging$6393%
  • Food & beverage$1,7219%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,410 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$62,019
Medicare patients
692
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban277$260,718
EntrestoSacubitril/Valsartan75$84,484
Repatha SureclickEvolocumab58$53,373
JardianceEmpagliflozin16$20,883
XareltoRivaroxaban22$14,542
VascepaIcosapent Ethyl11$9,109
Metoprolol Succinate342$3,856
Atorvastatin Calcium189$2,149
Losartan Potassium163$2,061
Isosorbide Mononitrate ErIsosorbide Mononitrate83$2,018
Carvedilol164$1,797
Rosuvastatin Calcium151$1,634
Lisinopril158$1,500
Nitroglycerin89$1,233
Ezetimibe73$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$229$84,48475 claims
Boehringer IngelheimJardiance$5,928$20,88316 claims
Johnson & JohnsonXarelto$204$14,54222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Elkin

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →